Gold dropped from a near eight-year high overnight as equities gained on the back of encouraging US manufacturing data and rising hopes for a potential COVID-19 vaccine.
Spot gold fell 0.6 per cent to $US1,770.57 per ounce by 1731 GMT, having earlier hit a peak since October 2012 at $US1788.96. US gold futures settled down 1.1 per cent, at $US1,779.90.
“A renewed sense of optimism over the U.S. economy recovering quicker than expected may fuel the risk-on mood, ultimately denting appetite for safe-haven assets including gold,” said FXTM analyst Lukman Otunuga.
US manufacturing activity rebounded in June, hitting its highest level in more than a year, bolstering the stock market along with hopes of a vaccine developed by BioNTech and Pfizer that has shown potential in early stage human trials.
“Gold remains in an uptrend on the daily charts but the momentum could be running out of steam,” Otunuga said, adding that if prices dip below $US1,765 that may open a path back towards $US1,747 and $US1,715.
The bullion surged over 13 per cent last quarter due to fears of a second wave of infections and as global central banks have bumped up stimulus measures and kept interest rates low to ease the economic blow from the pandemic.
Differences in how state governments are handling their economic shutdowns in the United States and the strong likelihood that there will be more stimulus are likely to support gold prices, said Jeffrey Sica, founder of Circle Squared Alternative Investments.
Reflecting high investor demand, holdings in the world’s largest gold-backed exchange-traded fund, SPDR Gold Trust, increased by 211.9 tonnes, or nearly 22 per cent, in the second quarter.
Other precious metals also declined, with silver falling 1.1 per cent to $US17.93. The metal earlier in the day hit its highest since late February.
Palladium slid 1.1 per cent to $US1,908.68 per ounce and platinum eased 0.4 per cent to $US813.15 per ounce.